Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Apixaban, an oral factor Xa inhibitor administered in fixed doses, may simplify the treatment of venous thromboembolism. METHODS: In this randomized, double-blind study, we compared apixaban (at a dose of 10 mg twice daily for 7 days, followed by 5 mg twice daily for 6 months) with conventional therapy (subcutaneous enoxaparin, followed by warfarin) in 5395 patients with acute venous thromboembolism. The primary efficacy outcome was recurrent symptomatic venous thromboembolism or death related to venous thromboembolism. The principal safety outcomes were major bleeding alone and major bleeding plus clinically relevant nonmajor bleeding. RESULTS: The primary efficacy outcome occurred in 59 of 2609 patients (2.3%) in the apixaban group, as compared with 71 of 2635 (2.7%) in the conventional-therapy group (relative risk, 0.84; 95% confidence interval [CI], 0.60 to 1.18; difference in risk [apixaban minus conventional therapy], -0.4 percentage points; 95% CI, -1.3 to 0.4). Apixaban was noninferior to conventional therapy (P<0.001) for predefined upper limits of the 95% confidence intervals for both relative risk (<1.80) and difference in risk (<3.5 percentage points). Major bleeding occurred in 0.6% of patients who received apixaban and in 1.8% of those who received conventional therapy (relative risk, 0.31; 95% CI, 0.17 to 0.55; P<0.001 for superiority). The composite outcome of major bleeding and clinically relevant nonmajor bleeding occurred in 4.3% of the patients in the apixaban group, as compared with 9.7% of those in the conventional-therapy group (relative risk, 0.44; 95% CI, 0.36 to 0.55; P<0.001). Rates of other adverse events were similar in the two groups. CONCLUSIONS: A fixed-dose regimen of apixaban alone was noninferior to conventional therapy for the treatment of acute venous thromboembolism and was associated with significantly less bleeding (Funded by Pfizer and Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00643201).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
Citations
Cites
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,065
Apixaban for Extended Treatment of Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Porcari, A., Raskob, G. E., & Weitz, J. I. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1207541 · Cited by 1,366
Self-citationPulmonary embolism and deep vein thrombosis
Goldhaber, S. Z., & Bounameaux, H. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61904-1 · Cited by 1,054
Farrington, C. P., & Manning, G. (1990) · Statistics in Medicine · doi:10.1002/sim.4780091208 · Cited by 657
Idraparinux versus Standard Therapy for Venous Thromboembolic Disease
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa064247 · Cited by 335
Cited by
Items 801–900 of 1,003
Direct oral anticoagulants: a guide for daily practice
Fontana, P., Robert‐Ebadi, H., Bounameaux, H., Boehlen, F., & Righini, M. (2016) · Swiss Medical Weekly · doi:10.4414/smw.2016.14286 · Cited by 22
Pathways for outpatient management of venous thromboembolism in a UK centre
Condliffe, R. A. (2016) · Thrombosis Journal · doi:10.1186/s12959-016-0120-2 · Cited by 17
Noble, S., Pease, N. J., Sui, J., Davies, J., Lewis, S., Malik, U., Alikhan, R., Prout, H., & Nelson, A. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-013321 · Cited by 17
Terleira‐Fernández, A. I., Lecumberri, R., Suárez‐Gea, M. L., Calvo, G., Vargas, E., & Gómez‐Outes, A. (2018) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0038-1642644 · Cited by 17
Beyer‐Westendorf, J., Klamroth, R., Kreher, S., Länger, F. P., Matzdorff, A. C., & Riess, H. B. (2019) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2019.0031 · Cited by 17
Deutsch, D., Romegoux, P., Boustière, C., Sabaté, J., Benamouzig, R., & Albaladejo, P. (2019) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284819851677 · Cited by 18
Hendriks, T., McGregor, S., Rakesh, S., Robinson, J., Ho, K. M., & Baker, R. I. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234048 · Cited by 17
Dager, W. E., & Hellwig, T. R. (2016) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp150960 · Cited by 16
Direct Oral Anticoagulants for Thromboprophylaxis in Patients with Antiphospholipid Syndrome
Efthymiou, M., Gates, C., Isenberg, D. A., & Cohen, H. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0036-1597902 · Cited by 17
Switching from warfarin to direct-acting oral anticoagulants: it is time to move forward!
Abdelnabi, M. H., Benjanuwattra, J., Okasha, O., Almaghraby, A. M., Saleh, Y., & Gerges, F. (2022) · The Egyptian Heart Journal · doi:10.1186/s43044-022-00259-9 · Cited by 17
Wu, O., Morris, S., Larsen, T. B., Skjøth, F., Evans, A., Bowrin, K., Wojciechowski, P., Margas, W., & Huelsebeck, M. (2022) · Cardiovascular Therapeutics · doi:10.1155/2022/2756682 · Cited by 16
“Neither the AMPLIFY trial nor our meta-analysis demonstrated a signi fi cant di ff er-ence between API and SoC regarding mortality [26].”
ResultHe, Q., Wei, Y., Qian, Y., & Zhong, M. (2024) · Journal of Intensive Medicine · doi:10.1016/j.jointm.2024.02.003 · Cited by 17
“[ 139 ] Currently, clinically employed FXa inhibitors include rivaroxaban, [ 140 ] apixaban, [ 141 ] edoxaban, [ 142 ] betrixaban, [ 123 ] and among others.”
Alberio, L. (2014) · Seminars in Hematology · doi:10.1053/j.seminhematol.2014.03.002 · Cited by 16
Advanced Management Options for Massive and Submassive Pulmonary Embolism
Malik, S., Bhardwaj, A., Eisen, M., & Gandhi, S. (2016) · US Cardiology Review · doi:10.15420/usc.2016.10.1.30 · Cited by 18
Desai, A., Desai, A., Calixte, R., Aparnath, M., Hindenburg, A., Salzman, S. H., & Mathew, J. P. (2016) · Lung · doi:10.1007/s00408-016-9898-8 · Cited by 16
Lanitis, T., Leipold, R. J., Hamilton, M., Rublee, D. A., Quon, P., Browne, C., & Cohen, A. T. (2017) · BMC Health Services Research · doi:10.1186/s12913-017-1995-8 · Cited by 16
“The AMPLIFY study was a non-inferiority trial that compared apixaban (10 mg twice a day [BID] for 7 days followed by 5 mg BID) to 7-day LMWH with concurrent initiation of VKA for 6 months in patients with acute VTE [12].”
BackgroundMethodInfluentialSelf-citationComparison of Anti-Xa Activity in Patients Receiving Apixaban or Rivaroxaban
Bookstaver, D. A., Sparks, K. S., Pybus, B. S., Davis, D. K., Marcsisin, S. R., & Sousa, J. C. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017738262 · Cited by 16
Yhim, H., Choi, W.-I., Kim, S., Nam, S.-H., Kim, K. H., Mun, Y., Oh, D., Hwang, H.-G., Lee, K., Song, E., et al. (2018) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2018.097 · Cited by 16
“Although the pivotal phase III trials testing DOACs included cancer patients, the results of these trials [9-13] and subsequent subgroup analysis [14-17] have been underpowered by the small number of cancer patients and the heterogeneity in definition of cancer for the trials [18].”
BackgroundPapakonstantinou, P. Ε., Tsioufis, C. P., Konstantinidis, D., Iliakis, P., Leontsinis, I., & Tousoulis, D. M. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200420150517 · Cited by 17
Efficacy and Safety of Direct-Acting Oral Anticoagulants (DOACs) in the Overweight and Obese
Doucette, K., Latif, H., Vakiti, A., Tefera, E. A., Patel, B. A., & Fitzpatrick, K. (2020) · Advances in Hematology · doi:10.1155/2020/3890706 · Cited by 16
“Additionally, safety parameters, namely, major bleeding and clinically relevant nonmajor bleeding (CRNMB), are reported to be lower in all patients taking DOACs when compared to VKAs [14].”
ResultInfluentialRahmanzade, R., Cabrera-Diaz, F., Zaugg, C., Schüetz, P., & Salili, A. R. (2020) · Thrombosis Journal · doi:10.1186/s12959-020-00227-w · Cited by 17
Torres, C. M., & Haut, E. R. (2020) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000771 · Cited by 18
Bleeding risk in patients with venous thromboembolic events treated with new oral anticoagulants
Wallvik, N., Renlund, H., & Själander, A. (2020) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02319-w · Cited by 16
“Compared to the two major clinical trials EINSTEINVTE and AMPLIFY the major bleeding rate is about 5% higher in absolute numbers [16, 17].”
ResultMai, V., Marceau-Ferron, E., Bertoletti, L., Lacasse, Y., Bonnet, S., Lega, J., & Provencher, S. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105317 · Cited by 19
Direct Acting Oral Anticoagulants Following Gastrointestinal Tract Surgery
Hakeam, H. A., Alkhani, M. A., Alyahya, Z., Alawaji, Z., & Ofori, S. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001142 · Cited by 17
Management of Venous Thromboembolism in Morbid Obesity With Rivaroxaban or Warfarin
Weaver, P. L., Ng, T. H., Breeden, T., Edwin, S. B., Haan, B. J., & Giuliano, C. A. (2022) · Annals of Pharmacotherapy · doi:10.1177/10600280221089008 · Cited by 16
A Systematic Review of Polygenic Models for Predicting Drug Outcomes
Siemens, A., Anderson, S. J., Rassekh, S. R., Ross, C. J., & Carleton, B. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12091394 · Cited by 18
Fatima, H., Nwankwo, I., Anam, M., Maharjan, S., Amjad, Z., Abaza, A., Vasavada, A. M., Sadhu, A., Valencia, C., & Khan, S. (2022) · Cureus · doi:10.7759/cureus.30230 · Cited by 19
Parker, K., Choudhuri, S., Lewis, P. J., Thachil, J. V., & Mitra, S. (2023) · BMC Nephrology · doi:10.1186/s12882-022-03041-w · Cited by 23
Xu, J.-X., Wang, G., Chen, X., Shen, Y., Wang, X., & Wang, H. (2023) · Thrombosis Journal · doi:10.1186/s12959-023-00456-9 · Cited by 16
Direct Oral Anticoagulants for Cancer-Associated Venous Thromboembolism
Masini, M., Toma, M., Spallarossa, P., Porto, I., & Ameri, P. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01428-y · Cited by 18
How we treat bleeding associated with direct oral anticoagulants.
Marano, G., Vaglio, S., Pupella, S., Liumbruno, G. M., & Franchini, M. (2016) · Europe PMC (PubMed Central) · doi:10.2450/2016.0180-15 · Cited by 18
Evaluation of anticoagulation selection for acute venous thromboembolism
Badreldin, H. A., Nichols, H., Rimsans, J., & Carter, D. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1417-5 · Cited by 16
Management of venous thromboembolism in myeloproliferative neoplasms
Barbui, T., & Stefano, V. D. (2016) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000312 · Cited by 17
Once versus twice daily enoxaparin for the initial treatment of acute venous thromboembolism
Trujillo‐Santos, J., Bergmann, J., Bortoluzzi, C., López-Reyes, R., Giorgi‐Pierfranceschi, M., López‐Sáez, J. B., Ferrazzi, P., Bascuñana, J., Suriñach, J. M., & Monréal, M. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13616 · Cited by 16
Uppuluri, E. M., Burke, K. R., Haaf, C. M., & Shapiro, N. L. (2017) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155217730129 · Cited by 16
Wakakura, S., Hara, F., Fujino, T., Hamai, A., Ohara, H., Kabuki, T., Harada, M., & Ikeda, T. (2017) · International Heart Journal · doi:10.1536/ihj.16-482 · Cited by 16
Pulmonary embolism: Care standards in 2018
Borohovitz, A., Weinberg, M. D., & Weinberg, I. (2017) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2017.12.005 · Cited by 16
Yan, Y., Zhang, C., Shen, L., Su, Y.-J., Liu, X., Wang, L., & Gu, Z. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00575 · Cited by 16
“Whereas, clinical trials of NOACs that specially aimed at patients with cancer are lacked, and only a minor proportion of cancer patients (<5%) was involved in NOACs studies (Schulman et al., 2009, 2014; Bauersachs et al., 2010; Goldhaber et al., 2011; Büller et al., 2012, 2013; Agnelli et al., 2013; Cohen et al., 201…”
BackgroundShort‐term outcomes of pulmonary embolism: A National Perspective
Shah, P., Arora, S., Kumar, V. M., Sharma, S., Shah, H., Tripathi, B., Sharma, P., Sharma, R., Savani, S., Qureshi, M. R., et al. (2018) · Clinical Cardiology · doi:10.1002/clc.23048 · Cited by 16
“With the introduction of direct factor Xa inhibitors, the incidence of major bleeding has decreased significantly compared with conventional vitamin K antagonist agents.(9,10) The oral direct thrombin inhibitor used in PE treatment also has a reversal agent now, thus improving the safety of these medications.”
BackgroundUdayachalerm, S., Rattanasiri, S., Angkananard, T., Attia, J. R., Sansanayudh, N., & Thakkinstian, A. (2018) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029618796339 · Cited by 16
“Previous evidence showed that NOACs were noninferior, and even superior in some cases to warfarin in stroke prevention and systemic embolism.(2,4-6,11) with lower risk of major bleeding(5) including intracranial hemorrhage (ICH),(2,4-6,12) and similar risk of major gastrointestinal bleeding.”
BackgroundStevens, H., Tran, H. A., Chunilal, S. D., & Maclachlan, K. H. (2019) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0038-1677019 · Cited by 18
Pylephlebitis treated with apixaban
Hale, G. R., Sakkal, L. A., & Galanis, T. (2019) · Hospital Practice · doi:10.1080/21548331.2019.1670476 · Cited by 16
“It has also been shown to be noninferior to warfarin in treating acute venous thromboembolism, with fewer major bleeding events [23].”
BackgroundCoons, E. M., Staubes, B. A., Casey, A. L., Elagizi-Youssef, S. A., Mohammed, A., Sharma, N., & Kline, E. R. (2021) · Annals of Pharmacotherapy · doi:10.1177/10600280211025050 · Cited by 16
Liu, X., Thompson, J. R., Phatak, H. M., Mardekian, J., Porcari, A. R., Johnson, M. R., & Cohen, A. T. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-07-0606 · Cited by 17
“gov/show/NCT00643201) study demonstrated that a fixed dose of apixaban alone (10 mg twice daily for 7 days followed by 5 mg twice daily for 6 months) was non-inferior to conventional therapy (subcutaneous enoxaparin followed by warfarin) for the treatment of acute VTE (composite of recurrent symptomatic VTE or VTE-rel…”
BackgroundSelf-citationthe COMMAND VTE Registry Investigators, Yamashita, Y., Morimoto, T., Amano, H., Takase, T., Hiramori, S., Kim, K., Oi, M., Akao, M., Kobayashi, Y., et al. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-018-1791-2 · Cited by 16
Management of pulmonary embolism: recent evidence and the new European guidelines
Konstantinides, S., & Torbicki, A. (2014) · European Respiratory Journal · doi:10.1183/09031936.00180414 · Cited by 19
Zalpour, A., & Oo, T. H. (2015) · Advances in Hematology · doi:10.1155/2015/920361 · Cited by 15
Anticoagulation therapy in 2015: where we are and where we are going
Weitz, J. I. (2015) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1194-6 · Cited by 15
Self-citationThrombosis, Hypercoagulable States, and Anticoagulants
Hollenhorst, M. A., & Battinelli, E. M. (2016) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2016.07.001 · Cited by 15
Kataruka, A., Kong, X., Haymart, B., Kline-Rogers, E. M., ALMANY, S. L., Kozłowski, J., Krol, G. D., Kaatz, S., McNamara, M. W., Froehlich, J. B., et al. (2017) · Vascular Medicine · doi:10.1177/1358863x16682863 · Cited by 25
Nazha, B., Pandya, B., Spyropoulos, A. C., & Kessler, C. M. (2018) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0038-1673690 · Cited by 16
Lutsey, P. L., Norby, F. L., Zakai, N. A., MacLehose, R. F., Chen, L. Y., Shah, S., Datta, Y. H., & Alonso, Á. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1541445 · Cited by 16
Venous thrombosis of the liver: current and emerging concepts in management
Naymagon, L. (2020) · Translational research · doi:10.1016/j.trsl.2020.04.012 · Cited by 15
Chaudhary, R., Pagali, S. R., Garg, J., Murad, M. H., Wysokiński, W. E., & McBane, R. D. (2020) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16549 · Cited by 15
Faqah, A., Sheikh, H. S., Bakar, M. A., Tayyaab, F., & Khawaja, S. (2020) · Thrombosis Journal · doi:10.1186/s12959-020-00221-2 · Cited by 15
Prevention and Treatment of Bleeding with Direct Oral Anticoagulants
Crawley, R. M., & Anderson, R. L. (2020) · Drugs · doi:10.1007/s40265-020-01345-5 · Cited by 15
Mavromanoli, A. C., Barco, S., & Konstantinides, S. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12509 · Cited by 16
Delluc, A., Ghanima, W., Kovacs, M. J., Shivakumar, S., Kahn, S. R., Sandset, P. M., Kearon, C., Mallick, R., & Rodger, M. A. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15537 · Cited by 16
Nakano, Y., Adachi, S., Nishiyama, I., Yasuda, K., Imai, R., Yoshida, M., Iwano, S., Kondo, T., Murohara, T., Ando, M., et al. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15636 · Cited by 15
Athanazio, R. A., Ceresetto, J. M., Marfil‐Rivera, L. J., Cesarman-Maus, G. N., Gálvez, K., Marques, M. A., Tabares, A. H., Santacruz, C. A. O., Santini, F. C., Corrales, L., et al. (2022) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296221082988 · Cited by 16
Self-citationJamieson, M. J., Byon, W., Dettloff, R. W., Crawford, M., Gargalovic, P. S., Merali, S. J., Onorato, J. M., Quintero, A., & Russ, C. (2022) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-022-00524-x · Cited by 16
“0) over 6 months for the outcome of VTE or VTErelated death, with significantly less major bleeding (MB) [46].”
BackgroundAmin, A., Bruno, A. S., Trocio, J. N., Lin, J., & Lingohr-Smith, M. (2015) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2015.21.10.965 · Cited by 17
Ahmed, Z., Hassan, S., & Salzman, G. A. (2016) · Current Drug Therapy · doi:10.2174/1574885511666160421145036 · Cited by 15
“The strengths of the AMPLIFY trial include low rate of loss to follow-up and good adherence to treatment by participants (INR therapeutic 61% of the time) [20].”
InfluentialDiverse management of isolated calf deep venous thrombosis in a university hospital
Garcia, R., Probeck, K., Elitharp, D., Gasparis, A. P., & Labropoulos, N. (2017) · Journal of Vascular Surgery Venous and Lymphatic Disorders · doi:10.1016/j.jvsv.2017.08.021 · Cited by 15
Uterine bleeding during anticoagulation in women with venous thromboembolism
Moustafa, F., Fernández, S. M., Fernández‐Capitán, C., Nieto, J. A., Pedrajas, J. M., Visonà, A., Valero, B., Marchena, P. J., Braester, A., & Monréal, M. (2017) · Thrombosis Research · doi:10.1016/s0049-3848(17)30058-0 · Cited by 16
Frappé, P., Cogneau, J., Gaboreau, Y., Abenhaïm, N., Bayen, M., Calafiore, M., Guichard, C., Jacquet, J.-P., Lacoin, F., Bertoletti, L., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175167 · Cited by 16
Direct Oral Anticoagulants and the Paradigm Shift in the Management of Venous Thromboembolism
Lim, H. Y., Nandurkar, H. H., & Ho, P. W. (2018) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0038-1637750 · Cited by 15
Review of Direct Oral Anticoagulants and Guide for Effective Drug Utilization
Khachatryan, T., Hauschild, C., Hoff, J., Contractor, T. A., Khachatryan, A., Tran, H. N., Matsuo, B., Jacobson, A. K., & Hilliard, A. A. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00344-6 · Cited by 15
Weycker, D. A., Wygant, G. D., Guo, J. D., Lee, T. T. H., Luo, X., Rosenblatt, L. C., Mardekian, J., Atwood, M., Hanau, A., & Cohen, A. T. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001081 · Cited by 16
“Findings from the AMPLIFY clinical trial demonstrated the efficacy and safety of apixaban (vs enoxaparin overlapped and followed by warfarin) for the treatment of acute symptomatic VTE, and these findings were supplemented by a post hoc time-course analysis and prespecified subgroup analyses.(1,2) Findings from a rece…”
BackgroundMethodInfluentialSelf-citationSchreuder, M., Reitsma, P. H., & Bos, M. H. A. (2020) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0040-1709134 · Cited by 15
Jones, K. (2020) · Federal Practitioner · doi:10.12788/fp.0058 · Cited by 15
Martín, A. J. M., Gallardo, E., Agnelli, G., Crespo, C., Forghani, M., Arumí, D., de Cabo, S. F., & Soto, J. (2022) · Journal of Medical Economics · doi:10.1080/13696998.2022.2087998 · Cited by 17
Self-citationTreating Acute Venous Thromboembolism — Shift with Care
Cushman, M. (2013) · New England Journal of Medicine · doi:10.1056/nejme1307413 · Cited by 15
Venous thromboembolism: current management
Stevens, H., Tran, H. A., & Gibbs, H. H. (2019) · Australian Prescriber · doi:10.18773/austprescr.2019.039 · Cited by 18
Doundoulakis, I., Antza, C., Karvounis, H. I., & Giannakoulas, G. A. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200506114450 · Cited by 14
Ткачева, О. Н., Vorobyeva, N. M., Kotovskaya, Y. V., Рунихина, Н. К., Strazhesko, I. D., Вадимовна, В. С., Drapkina, O. M., Komarov, A. L., Orlova, Y. A., Панченко, Е. П., et al. (2021) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2021-2847 · Cited by 15
Simaan, N. M., Metanis, I., Honig, A., Hallevi, H., Filioglo, A., Mendel, R., Barnea, R., Naftali, J., Auriel, E., Aladdin, S., et al. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1404099 · Cited by 14
“Over the last decade, DOACs became the treatment of choice for atrial fibrillation and deep venous thrombosis due it clear benefits over VKA (8, 28).”
BackgroundEdoxaban, a Novel Oral Factor Xa Inhibitor
Minor, C., Tellor, K. B., & Armbruster, A. L. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015579426 · Cited by 14
Pharmacotherapy with oral Xa inhibitors for venous thromboembolism
Vanassche, T., Vandenbriele, C., Peerlinck, K., & Verhamme, P. B. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.999043 · Cited by 16
“2 Similarities in trials The Phase III programs of rivaroxaban [8,9], apixaban [10,11] and edoxaban [12] are summarized in Table 3.”
BackgroundApproach to the new oral anticoagulants in family practice: Part 1: comparing the options
Douketis, J. D., Bell, A., Eikelboom, J. W., & Liew, A. (2014) · Europe PMC (PubMed Central) · doi:10.25405/ncl.34238934 · Cited by 18
Direct oral anticoagulants: efficacy and safety in patient subgroups
Mavrakanas, T. A., Samer, C. F., Fontana, P., & Perrier, A. (2015) · Swiss Medical Weekly · doi:10.4414/smw.2015.14081 · Cited by 14
Thrombosis of atypical location: how to treat patients in the era of direct oral anticoagulants?
Mimier, M. K., Janczak, D. T., McBane, R. D., Houghton, D. E., & Wysokiński, W. E. (2018) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.4333 · Cited by 18
Al‐Jazairi, A. S., Alshaykh, H. A., Salvo, G. D., Vol, E. B. D., & Al‐Halees, Z. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028019829860 · Cited by 14
An update on neurocritical care for intracerebral hemorrhage
Reyes, R. G., Viswanathan, M., & Aiyagari, V. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1618709 · Cited by 16
Safieddine, M., Chapelle, C., Ollier, É., Ferdynus, C., Bertoletti, L., Mismetti, P., Cucherat, M., & Laporte, S. (2020) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2020.10.013 · Cited by 14
Palareti, G., Antonucci, E., Legnani, C., Mastroiacovo, D., Poli, D., Prandoni, P., Tosetto, A., Pengo, V., Testa, S., & Ageno, W. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-040449 · Cited by 15
Nguyen, S. N., Ruegger, M. C., Salazar, E., Dreucean, D., Tatara, A. W., & Donahue, K. R. (2021) · Journal of Pharmacy Practice · doi:10.1177/08971900211009075 · Cited by 14
“(%) Caucasian 117 (69) 89 (66) 28 (82) Black 45 (27) 40 (30) 5 (15) Other 7 (4) 6 (4) 1 (3) Height (in), median (IQR) 67 (64-70) 67 (64-70) 66 (64-70) Weight (kg), median (IQR) 81.”
Giles, J. A., Balasetti, V. K. S., & Zazulia, A. R. (2021) · Neurocritical Care · doi:10.1007/s12028-021-01244-x · Cited by 14
“Evidence for the use of rivaroxaban [10– 12] and apixaban [12, 13] remains limited to small case series, which, again, showed comparable rates of recanalization between these NOACs and VKAs.”
BackgroundEffects of oral anticoagulant therapy in patients with pulmonary diseases
Lai, J., Feng, S., Xu, S., & Liu, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.987652 · Cited by 15
“(2013) (40) Pulmonary embolism Apixaban group: 10mg of”
BackgroundReview article: the safety of anticoagulants and antiplatelet agents in patients with cirrhosis
Ma, J., Chalasani, N., Schwantes-An, T.-H. L., & Bjornsson, E. S. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17297 · Cited by 14
Ahuja, T., Raco, V., Bhardwaj, S., & Green, D. (2023) · Advances in Hematology · doi:10.1155/2023/9511499 · Cited by 16
Almajdi, A., Almutairi, S., & Alharbi, M. (2023) · Thrombosis Research · doi:10.1016/j.thromres.2023.06.027 · Cited by 15
Laville, S. M., Couchoud, C., Bauwens, M., Vacher-Coponat, H., Choukroun, G. J., Liabeuf, S., Collaborators, F. T. R., Honoré, N., Boime, S., Gardeur-Algros, E., et al. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae042 · Cited by 19
“Indeed, in clinical trials, VKAs and DOACs have been compared in patients with atrial fibrillation [5 –8 ] and acute venous thromboembolism [9 –11 ].”
Abdel‐Azeim, S., Oliva, R., Chermak, E., CRISTOFARO, R. D., & Cavallo, L. (2014) · Biochemistry · doi:10.1021/bi500770p · Cited by 14
Current State of Anticoagulants to Treat Deep Venous Thrombosis
Vo, T. L., Vazquez, S. R., & Rondina, M. T. (2014) · Current Cardiology Reports · doi:10.1007/s11886-013-0463-2 · Cited by 14
Toth, P. P. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s88088 · Cited by 19
Management of bleeding complications in patients with cancer on DOACs
Schulman, S., Shrum, J., & Majeed, A. (2016) · Thrombosis Research · doi:10.1016/s0049-3848(16)30113-x · Cited by 16
“AMPLIFY [28] Apixaban VKA 6m 2704 81 2691 87 11”
BackgroundInfluentialKabrhel, C. (2017) · Seminars in Interventional Radiology · doi:10.1055/s-0036-1597760 · Cited by 15
Bauersachs, R. M., Agnelli, G., Gitt, A. K., Monréal, M., Mismetti, P., Willich, S. N., Laeis, P., Fronk, E., Bramlage, P., & Cohen, A. T. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.07.029 · Cited by 15
Self-citation
Metadata
- Authors
- Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., & Weitz, J. I.
- Affiliations
- University of Perugia (IT)
- Amsterdam UMC Location University of Amsterdam (NL)
- King's College Hospital (GB)
- Pfizer (United States) (US)
- Flinders University (AU)
- University of Oklahoma Health Sciences Center (US)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-08-29
- Volume
- 369
- Issue
- 9
- Pages
- 799-808
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2166402206
- Cited by
- 2,324
- References
- 13
- Citations by year
- 2026: 109 · 2025: 101 · 2024: 134 · 2023: 134 · 2022: 162 · 2021: 193 · 2020: 224 · 2019: 193 · 2018: 213 · 2017: 191 · 2016: 234 · 2015: 198 · 2014: 184 · 2013: 51
- FWCI
- 194.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- apixaban, acute venous thromboembolism, factor Xa inhibitors, oral anticoagulation, enoxaparin, warfarin, recurrent venous thromboembolism, major bleeding, non-inferiority, fixed-dose regimen, direct oral anticoagulants, anticoagulation duration, venous thromboembolism
- MeSH terms
- Acute Disease, Administration, Oral, Adult, Aged, Anticoagulants, Double-Blind Method, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Pyrazoles, Pyridones, Warfarin, Treatment Outcome, Enoxaparin, Kaplan-Meier Estimate, Venous Thromboembolism, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.